Two UK advocacy groups demand revocation of key provisions in a new trade deal with the US over concerns about outsider influence on drug cost-effectiveness, threatening legal action if not addressed.
Two prominent advocacy groups in the United Kingdom are demanding that the government revoke regulations at the core of a recently finalized trade agreement with the U.S. These groups argue that the deal poses significant risks to patient access and affordability due to provisions allowing outsiders to influence decisions on the cost-effectiveness of medicines. Under the pharmaceuticals section of this trade pact, which was concluded last month, the Trump administration committed to eliminating tariffs on medicine exports from the UK for at least three years. This makes the U.K. the only country with tariff-free access to the American market for pharmaceutical products. The deal is particularly noteworthy as it will significantly boost the economic importance of the UK's pharmaceutical sector by increasing government spending on medicines from 0.3% of GDP to 0.35% by 2028 and potentially up to 0.6% by 2035, while also raising prices paid by the National Health Service (NHS) for drugs by 25% and reducing the maximum rebate the NHS can receive from drug manufacturers to just 15%. In response to these changes, two key UK advocacy groups have expressed deep concern. They argue that such provisions could undermine public health by allowing foreign interests to exert undue influence over decisions about which medicines are deemed cost-effective for government funding. If the government fails to address these concerns and withdraws the controversial regulations, the advocacy groups plan to take legal action against the deal. The threat of court intervention underscores the growing unease among stakeholders in the UK healthcare system regarding the implications of this trade agreement with the U.S.
Continue to STAT+ to read the full story…
